Related Experiment Video
Updated: Oct 15, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Idiopathic Pulmonary Comorbidities and Mechanisms
Maricica Pacurari1, Amal Mitra2, Timothy Turner1
1Department of Biology, College of Science, Engineering, and Technology, Jackson State University, Jackson, MS 39217, USA.
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor survival. Research shows IPF may be a risk factor for other conditions, necessitating further study for new treatments.
Area of Science:
- Pulmonology
- Pathogenesis
- Disease Risk Factors
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause, leading to significant lung function decline and low survival rates (3-5 years post-diagnosis).
- Recent advancements have improved IPF management through understanding disease mechanisms, leading to new drugs like pirfenidone and nintedanib.
- Recognition of IPF's cofactors and comorbidities has also enhanced patient outcome management.
Purpose of the Study:
- To review scientific evidence evaluating Idiopathic pulmonary fibrosis (IPF) as a potential risk factor for other diseases.
- To explore the complex molecular and cellular mechanisms underlying IPF development and its associated comorbidities.
- To identify novel therapeutic targets for IPF and associated conditions.
Main Methods:
- Systematic review of existing scientific literature.
- Analysis of molecular and cellular mechanisms implicated in IPF pathogenesis.
- Evaluation of comorbidities associated with IPF.
Main Results:
- Evidence suggests Idiopathic pulmonary fibrosis (IPF) is a significant risk factor for developing other diseases.
- The complexity of IPF's molecular and cellular pathways contributes to its role as a risk factor.
- Comorbidities associated with IPF further complicate disease management and outcomes.
Conclusions:
- Significant progress has been made in understanding Idiopathic pulmonary fibrosis (IPF) mechanisms and management.
- Further research is crucial to fully elucidate IPF pathogenesis.
- Identifying novel therapeutic targets for IPF is essential, alongside understanding its role in other diseases where IPF is a risk factor.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

